Keywords: Celgene, Pomalyst, Pomalidomide, Multiple myeloma, USA, FDA

FDA approves Celgene's Pomalyst for advanced multiple myeloma

Article | 11 February 2013

Print This

The US Food and Drug Administration on Friday approved biotech firm Celgene’s (Nasdaq: CELG) Pomalyst (pomalidomide) to treat ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in